Eric Lefebvre Biography and Net Worth

Insider of Pliant Therapeutics

As Pliant’s chief medical officer, Éric Lefebvre, M.D. is responsible for leading the company’s clinical development strategy and clinical operations for its portfolio of product candidates. Prior to joining Pliant, Dr. Lefebvre was head of clinical research and development for non-alcoholic steatohepatitis (NASH) at Allergan, where he advanced cenicriviroc for the treatment of patients with NASH into Phase 3 trials. Previously, he was chief medical officer at Tobira Therapeutics, whose focus was the development and commercialization of therapies to treat liver disease, inflammation, fibrosis and HIV, prior to the company being acquired by Allergan in 2016. Dr. Lefebvre also led global clinical development, global medical affairs and commercialization of novel treatments for HIV and hepatitis C at Janssen Pharmaceuticals for 10 years prior to starting his pharmaceutical career at GSK Canada. This was preceded by 15 years of providing primary care and conducting clinical research in HIV and hepatitis at Clinique Medicale L’Actuel in Montreal, Canada.

Dr. Lefebvre earned a B.S. from Edouard-Montpetit College and an M.D. from the University of Montreal.

What is Eric Lefebvre's net worth?: The estimated net worth of Eric Lefebvre is at least $3.06 million as of July 10th, 2024. Lefebvre owns 213,052 shares of Pliant Therapeutics stock worth more than $3,061,557 as of December 18th. This net worth approximation does not reflect any other investments that Lefebvre may own. Learn More about Eric Lefebvre's net worth.
How do I contact Eric Lefebvre?: The corporate mailing address for Lefebvre and other Pliant Therapeutics executives is 260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA, 94080. Pliant Therapeutics can also be reached via phone at 650-481-6770 and via email at [email protected]. Learn More on Eric Lefebvre's contact information.
Has Eric Lefebvre been buying or selling shares of Pliant Therapeutics?: Eric Lefebvre has not been actively trading shares of Pliant Therapeutics within the last three months. Most recently, Eric Lefebvre sold 12,319 shares of the business's stock in a transaction on Wednesday, July 10th. The shares were sold at an average price of $11.56, for a transaction totalling $142,407.64. Following the completion of the sale, the insider now directly owns 213,052 shares of the company's stock, valued at $2,462,881.12. Learn More on Eric Lefebvre's trading history.
Who are Pliant Therapeutics' active insiders?: Pliant Therapeutics' insider roster includes Bernard Coulie (CEO), and Eric Lefebvre (Insider). Learn More on Pliant Therapeutics' active insiders.
Are insiders buying or selling shares of Pliant Therapeutics?: In the last year, insiders at the sold shares 8 times. They sold a total of 120,081 shares worth more than $1,674,386.31. The most recent insider tranaction occured on July, 10th when insider Eric Lefebvre sold 12,319 shares worth more than $142,407.64. Insiders at Pliant Therapeutics own 6.4% of the company. Learn More about insider trades at Pliant Therapeutics.
Information on this page was last updated on 7/10/2024.

Eric Lefebvre Insider Trading History at Pliant Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/10/2024	Sell	12,319	$11.56	$142,407.64	213,052
7/17/2023	Sell	22,321	$18.01	$402,001.21	167,215
3/30/2023	Sell	11,245	$26.52	$298,217.40	145,786
1/23/2023	Sell	67,500	$34.48	$2,327,400.00	76,926
12/20/2022	Sell	10,887	$19.10	$207,941.70	144,426
10/25/2022	Sell	5,000	$25.05	$125,250.00	133,437
7/11/2022	Sell	3,000	$20.00	$60,000.00	138,436
6/18/2021	Sell	12,500	$28.87	$360,875.00	140,830
3/18/2021	Sell	12,500	$39.41	$492,625.00	150,715
12/18/2020	Sell	12,500	$26.54	$331,750.00	167,792

Eric Lefebvre Buying and Selling Activity at Pliant Therapeutics

Pliant Therapeutics Company Overview

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Today's Range

Now: $14.37

$13.70

$14.66

50 Day Range

MA: $14.00

$11.48

$15.70

2 Week Range

Now: $14.37

$10.22

$19.62

Volume

368,155 shs

Average Volume

457,554 shs

Market Capitalization

$874.47 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.05

AI Crypto Tool Could Send One Coin SOARING…

From Crypto 101 Media | Ad

The #1 AI Coin to Buy Rapid growth predicted for little-known AI crypto project

Discover our #1 crypto pick before it's too late.